BioPharmX Corp Receives a Buy from Maxim Group


Maxim Group analyst Anthony Vendetti maintained a Buy rating on BioPharmX Corp (NYSE: BPMX) today and set a price target of $1.50. The company’s shares closed yesterday at $0.25.

Vendetti noted:

“F1Q19 (Apr) results were relatively inline with our estimates and consensus. 2018, cash and cash equivalents were $10.9M, up from $7.6M at January 31, 2018, due primarily to warrant exercises that provided about $7M to the company. BPMX announced that, as of June 1, 2018, it has regained compliance with the NYSE American’s continued listing standards with respect to its low stock price.”

According to TipRanks.com, Vendetti is a 4-star analyst with an average return of 11.7% and a 59.0% success rate. Vendetti covers the Healthcare sector, focusing on stocks such as Restoration Robotics Inc, Xtant Medical Holdings, and Milestone Scientific.

BioPharmX Corp has an analyst consensus of Moderate Buy, with a price target consensus of $1.50.

See today’s analyst top recommended stocks >>

Based on BioPharmX Corp’s latest earnings release for the quarter ending April 30, the company reported a quarterly GAAP net loss of $4.4 million. In comparison, last year the company had a GAAP net loss of $5.4 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

BioPharmX Corp. engages in providing healthcare products through platform technologies for pharmaceutical, over-the-counter and supplement applications in dermatology. Its platforms include Topical Gel, Injectable, and Encapsulation. The company was founded by James R. Pekarsky and Anja B. Krammer on August 30, 2010 and is headquartered in Menlo Park, CA.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts